FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164553008> ?p ?o ?g. }

• W2164553008 endingPage "2976" @default.
• W2164553008 startingPage "2968" @default.
• W2164553008 abstract "Abstract Purpose: To establish the maximum tolerated dose of lonafarnib, a novel farnesyltransferase inhibitor, in combination with paclitaxel in patients with solid tumors and to characterize the safety, tolerability, dose-limiting toxicity, and pharmacokinetics of this combination regimen. Experimental Design: In a Phase I trial, lonafarnib was administered p.o., twice daily (b.i.d.) on continuously scheduled doses of 100 mg, 125 mg, and 150 mg in combination with i.v. paclitaxel at doses of 135 mg/m2 or 175 mg/m2 administered over 3 h on day 8 of every 21-day cycle. Plasma paclitaxel and lonafarnib concentrations were collected at selected time points from each patient. Results: Twenty-four patients were enrolled; 21 patients were evaluable. The principal grade 3/4 toxicity was diarrhea (5 of 21 patients), which was most likely due to lonafarnib. dose-limiting toxicities included grade 3 hyperbilirubinemia at dose level 3 (100 mg b.i.d. lonafarnib and 175 mg/m2 paclitaxel); grade 4 diarrhea and grade 3 peripheral neuropathy at dose level 3A (125 mg b.i.d. lonafarnib and 175 mg/m2 paclitaxel); and grade 4 neutropenia with fever and grade 4 diarrhea at level 4 (150 mg b.i.d. lonafarnib and 175 mg/m2 paclitaxel). The maximum tolerated dose established by the continual reassessment method was lonafarnib 100 mg b.i.d. and paclitaxel 175 mg/m2. Paclitaxel appeared to have no effect on the pharmacokinetics of lonafarnib. The median duration of therapy was eight cycles, including seven cycles with paclitaxel. Six of 15 previously treated patients had a durable partial response, including 3 patients who had previous taxane therapy. Notably, two of five patients with taxane-resistant metastatic non-small cell lung cancer had partial responses. Conclusions: When combined with paclitaxel, the recommended dose of lonafarnib for Phase II trials is 100 mg p.o. twice daily with 175 mg/m2 of paclitaxel i.v. every 3 weeks. Additional studies of lonafarnib in combination regimens appear warranted, particularly in patients with non-small cell lung cancer." @default.
• W2164553008 created "2016-06-24" @default.
• W2164553008 creator A5002347804 @default.
• W2164553008 creator A5004577239 @default.
• W2164553008 creator A5005738281 @default.
• W2164553008 creator A5008593691 @default.
• W2164553008 creator A5008790176 @default.
• W2164553008 creator A5009466654 @default.
• W2164553008 creator A5010399375 @default.
• W2164553008 creator A5016648330 @default.
• W2164553008 creator A5016730511 @default.
• W2164553008 creator A5017187936 @default.
• W2164553008 creator A5033695214 @default.
• W2164553008 creator A5034758372 @default.
• W2164553008 creator A5035909919 @default.
• W2164553008 creator A5043275986 @default.
• W2164553008 creator A5059710197 @default.
• W2164553008 creator A5062291677 @default.
• W2164553008 creator A5067386747 @default.
• W2164553008 creator A5069072872 @default.
• W2164553008 creator A5073466449 @default.
• W2164553008 creator A5077763767 @default.
• W2164553008 creator A5085188591 @default.
• W2164553008 date "2004-05-01" @default.
• W2164553008 modified "2023-09-29" @default.
• W2164553008 title "Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors" @default.
• W2164553008 cites W1458982 @default.
• W2164553008 cites W1836451026 @default.
• W2164553008 cites W1873121398 @default.
• W2164553008 cites W1874925441 @default.
• W2164553008 cites W1883066466 @default.
• W2164553008 cites W1930536528 @default.
• W2164553008 cites W1955547739 @default.
• W2164553008 cites W1965995529 @default.
• W2164553008 cites W1968349419 @default.
• W2164553008 cites W1969998496 @default.
• W2164553008 cites W1970245450 @default.
• W2164553008 cites W2008431826 @default.
• W2164553008 cites W2010207338 @default.
• W2164553008 cites W2017098460 @default.
• W2164553008 cites W2036699032 @default.
• W2164553008 cites W2047785503 @default.
• W2164553008 cites W2059250716 @default.
• W2164553008 cites W2069764898 @default.
• W2164553008 cites W2077861570 @default.
• W2164553008 cites W2086589373 @default.
• W2164553008 cites W2088500030 @default.
• W2164553008 cites W2089642031 @default.
• W2164553008 cites W2113048420 @default.
• W2164553008 cites W2123620482 @default.
• W2164553008 cites W2133362776 @default.
• W2164553008 cites W2145978772 @default.
• W2164553008 cites W2154468846 @default.
• W2164553008 cites W2163036089 @default.
• W2164553008 cites W2255894651 @default.
• W2164553008 cites W2337358073 @default.
• W2164553008 cites W4236901939 @default.
• W2164553008 doi "https://doi.org/10.1158/1078-0432.ccr-03-0412" @default.
• W2164553008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15131032" @default.
• W2164553008 hasPublicationYear "2004" @default.
• W2164553008 type Work @default.
• W2164553008 sameAs 2164553008 @default.
• W2164553008 citedByCount "69" @default.
• W2164553008 countsByYear W21645530082012 @default.
• W2164553008 countsByYear W21645530082013 @default.
• W2164553008 countsByYear W21645530082014 @default.
• W2164553008 countsByYear W21645530082015 @default.
• W2164553008 countsByYear W21645530082017 @default.
• W2164553008 countsByYear W21645530082019 @default.
• W2164553008 countsByYear W21645530082021 @default.
• W2164553008 countsByYear W21645530082023 @default.
• W2164553008 crossrefType "journal-article" @default.
• W2164553008 hasAuthorship W2164553008A5002347804 @default.
• W2164553008 hasAuthorship W2164553008A5004577239 @default.
• W2164553008 hasAuthorship W2164553008A5005738281 @default.
• W2164553008 hasAuthorship W2164553008A5008593691 @default.
• W2164553008 hasAuthorship W2164553008A5008790176 @default.
• W2164553008 hasAuthorship W2164553008A5009466654 @default.
• W2164553008 hasAuthorship W2164553008A5010399375 @default.
• W2164553008 hasAuthorship W2164553008A5016648330 @default.
• W2164553008 hasAuthorship W2164553008A5016730511 @default.
• W2164553008 hasAuthorship W2164553008A5017187936 @default.
• W2164553008 hasAuthorship W2164553008A5033695214 @default.
• W2164553008 hasAuthorship W2164553008A5034758372 @default.
• W2164553008 hasAuthorship W2164553008A5035909919 @default.
• W2164553008 hasAuthorship W2164553008A5043275986 @default.
• W2164553008 hasAuthorship W2164553008A5059710197 @default.
• W2164553008 hasAuthorship W2164553008A5062291677 @default.
• W2164553008 hasAuthorship W2164553008A5067386747 @default.
• W2164553008 hasAuthorship W2164553008A5069072872 @default.
• W2164553008 hasAuthorship W2164553008A5073466449 @default.
• W2164553008 hasAuthorship W2164553008A5077763767 @default.
• W2164553008 hasAuthorship W2164553008A5085188591 @default.
• W2164553008 hasConcept C112705442 @default.
• W2164553008 hasConcept C126322002 @default.
• W2164553008 hasConcept C181199279 @default.
• W2164553008 hasConcept C185592680 @default.
• W2164553008 hasConcept C197934379 @default.

• next